E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
CLINICAL DIAGNOSIS OF GASTROESOPHAGEAL REFLUX DISEASE GERD in neonates and preterm infants |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10017885 |
E.1.2 | Term | Gastrooesophageal reflux disease |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine whether or not consistent exposures can be achieved in neonates and preterm infants with presumed GERD receiving oral doses of pantoprazole. |
|
E.2.2 | Secondary objectives of the trial |
1.To characterize the pharmacokinetics PK of oral pantoprazole after a single dose and at steady state when consistent exposures can be achieved in neonates and preterm infants with presumed GERD at doses expected to produce exposures similar to older children and adults given standard doses. 2.To provide the pharmacodynamic PD assessment at baseline, and at steady state after the final dose of pantoprazole by measurement of intragastric and intraesophageal pH in neonates and preterm infants with presumed GERD. 3.To characterize the change in clinical GERD and respiratory symptoms from baseline, after single- and multiple- doses of pantoprazole in neonates and preterm infants with presumed GERD. 4.To describe the safety of pantoprazole in neonates and preterm infants with presumed GERD throughout the study. |
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
1.Male or female hospitalized patients admitted to a neonatal intensive care unit NICU or special care nursery, at the time of enrollment. 2.Have a clinical indication for acid suppression to treat a presumptive diagnosis of GERD based on clinical symptoms suggestive of GERD and/or objective tests diagnostic of GERD. NOTE Disorders associated with or worsened by GERD, objective tests suggestive of GERD, and/or aspiration in conjunction with GERD should also be noted. These are considered supportive documentation of the clinical diagnosis 3.Be either term or post-term infants within the neonatal period 28 days , or be preterm infants with a corrected age of less than 44 weeks. 4.Have a body weight of at least 1500 grams. 5.Patients must be able to tolerate oral feeding and swallow the test article |
|
E.4 | Principal exclusion criteria |
1. Cardiovascular instability, life-threatening arrhythmia, previous cardiopulmonary arrest, or mechanical ventilation.2. Known human immunodeficiency virus HIV or clinical manifestations of acquired immune deficiency syndrome AIDS or other significant immunodeficiency disorder or malignancy.3. Clinically significant laboratory test abnormality a. Aspartate aminotransferase AST or alanine aminotransferase ALT level 2 times upper limit of normal ULN .b. Alkaline phosphatase 2 times ULN age-corrected .4. Known history of positive serologic test for hepatitis B surface antigen HBsAg or hepatitis C virus HCV antibody or RNA.5. Known hypersensitivity to proton pump inhibitors PPIs , including pantoprazole.6. For PK Patients History of treatment with PPIs within 24 hours before the first 1st dose of test article.For PK/PD or PD Patients History of treatment with PPIs within 7 days before the first 1st dose of test article.7. For PK Patients Use of histamine-2-receptor antagonists H2RAs within 24 hours before the first 1st dose of test article. For PK/PD or PD Patients Use of H2RAs within 3 days before the first 1st dose of test article.8. Use of antacids within 2 hours before or after test article administration. Use of antacids is also prohibited 2 hours before or during pH-metry.9. Use of warfarin, carbamazepine, or phenytoin as well as rifampin for any disorder from at least 24 hours before the 1st dose of test article until after the final study procedure. 10.Significant renal or hepatic disease. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Clinical Symptoms Evaluation Pharmacokinetics -Single-dose PK Profiling -Multiple-dose PK Profiling Pharmacodynamics -Single-dose PD Profiling -Multiple-dose PDProfiling |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | Information not present in EudraCT |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 9 |